Genomma Lab Internacional (GNMLF) Stock Price, News & Analysis

Company Overview

Genomma Lab Internacional, S.A.B. de C.V. (OTCMKTS: GNMLF) is a Mexico-based consumer healthcare and personal care company. It develops, markets and distributes over-the-counter medicines, medical devices, cosmetics and hygiene products, primarily through retail pharmacies, supermarkets and other consumer channels.

The company’s portfolio includes products for areas such as pain relief, respiratory health, gastrointestinal care, dermatology, hair care and skin care. Its recognized brands include Asepxia, Cicatricure, Goicoechea, Tío Nacho, Silka and Next, although product availability varies by market.

Genomma Lab was established in Mexico in 1996 and has expanded its operations across Latin America, with a presence that has included markets such as Argentina, Brazil, Chile, Colombia, Ecuador and Peru, as well as the United States. The company is headquartered in Mexico City and is listed on the Mexican Stock Exchange under the symbol LAB.

Key Stats

• Today's Range: $0.72 to $0.72
• 50-Day Range: $0.69 to $0.83
• 52-Week Range: $0.69 to $1.08
• Volume: N/A
• Average Volume: 22,825 shs
• Market Capitalization: N/A
• P/E Ratio: 0.42
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Genomma Lab Internacional Stock Analysis - MarketRank™

Genomma Lab Internacional scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Genomma Lab Internacional has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Genomma Lab Internacional has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Genomma Lab Internacional is 0.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.20.

Price to Earnings Ratio vs. Sector

The P/E ratio of Genomma Lab Internacional is 0.42, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 37.20.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Genomma Lab Internacional has a short interest ratio ("days to cover") of 417.85, which indicates bearish sentiment.

Change versus previous month

Short interest in Genomma Lab Internacional has recently decreased by 20.92%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genomma Lab Internacional does not currently pay a dividend.

Dividend Growth

Genomma Lab Internacional does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Genomma Lab Internacional this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genomma Lab Internacional insiders have not sold or bought any company stock.

Percentage Held by Institutions

36.55% of the stock of Genomma Lab Internacional is held by institutions.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:GNMLF
• CIK: N/A
• Web: www.genommalab.com
• Phone: 525550810000
• Fax: N/A
• Employees: 1,465
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.42
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A